Article Text

Download PDFPDF

Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools
  1. Piet van Riel1,2,
  2. Rieke Alten3,
  3. Bernard Combe4,
  4. Diana Abdulganieva5,
  5. Paola Bousquet6,
  6. Molly Courtenay7,
  7. Cinzia Curiale8,
  8. Antonio Gómez-Centeno9,
  9. Glenn Haugeberg10,
  10. Burkhard Leeb11,12,13,
  11. Kari Puolakka14,
  12. Angelo Ravelli15,
  13. Bernhard Rintelen11,12 and
  14. Piercarlo Sarzi-Puttini16
  1. 1Radboud University Medical Centre, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, The Netherlands
  2. 2Department of Rheumatology, Bernhoven, Uden, The Netherlands
  3. 3Department Internal Medicine, Rheumatology, Schlosspark Klinik University Medicine Berlin, Berlin, Germany
  4. 4Département de Rhumatologie, Hôpital Lapeyronie, Montpellier Université, Montpellier, France
  5. 5Department of Internal Medicine, Kazan State Medical University, Kazan, Russia
  6. 6Pfizer Regional Medical Team, Rome, Italy
  7. 7School of Healthcare Sciences, College of Biomedical and Life Sciences, Cardiff University, Wales, UK
  8. 8Pfizer, Rome, Italy
  9. 9Department of Rheumatology, Parc Taulí Hospital Universitari, Sabadell, Spain
  10. 10Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway
  11. 11Landesklinikum Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria
  12. 12Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria
  13. 13Department for Rheumatology and Immunology, Medical University of Graz, Graz, Austria
  14. 14Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland
  15. 15University of Genoa and Istituto Giannina Gaslini, Genoa, Italy
  16. 16Department of Internal Medicine, University of Milan, Milano, Italy
  1. Correspondence to Professor Piet van Riel; piet.vanriel{at}radboudumc.nl

Abstract

Treating to target by monitoring disease activity and adjusting therapy to attain remission or low disease activity has been shown to lead to improved outcomes in chronic rheumatic diseases such as rheumatoid arthritis and spondyloarthritis. Patient-reported outcomes, used in conjunction with clinical measures, add an important perspective of disease activity as perceived by the patient. Several validated PROs are available for inflammatory arthritis, and advances in electronic patient monitoring tools are helping patients with chronic diseases to self-monitor and assess their symptoms and health. Frequent patient monitoring could potentially lead to the early identification of disease flares or adverse events, early intervention for patients who may require treatment adaptation, and possibly reduced appointment frequency for those with stable disease. A literature search was conducted to evaluate the potential role of patient self-monitoring and innovative monitoring of tools in optimising disease control in inflammatory arthritis. Experience from the treatment of congestive heart failure, diabetes and hypertension shows improved outcomes with remote electronic self-monitoring by patients. In inflammatory arthritis, electronic self-monitoring has been shown to be feasible in patients despite manual disability and to be acceptable to older patients. Patients' self-assessment of disease activity using such methods correlates well with disease activity assessed by rheumatologists. This review also describes several remote monitoring tools that are being developed and used in inflammatory arthritis, offering the potential to improve disease management and reduce pressure on specialists.

  • Rheumatoid Arthritis
  • Patient perspective
  • Disease Activity

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors PvR, RA and BC are joint lead authors and contributed equally. DA, PB, MC, CC, AG-C, GH, BL, KP, AR, BR and PS-P contributed equally.

  • Funding Initial drafting and subsequent medical writing support was provided by Clare Griffith, Synergy, London, UK and funded by Pfizer.

  • Competing interests RA has received research grants and honoraria from the speaker's bureau from Pfizer. BC has received honorarium from Pfizer. DA has received honoraria from Pfizer, MSD and UCB. PB is an employee of Pfizer. CC is an employee of Pfizer. GH is a founder and shareholder of the company DiaGraphIT, manufacturing GoTreatIT Rheuma. BL has received research grants as well as honoraria from Centocor, Abbott, Amgen, Aesca, UCB, Roche, MSD, Celltrion, Schering-Plough, Wyeth, Pfizer, BMS, Jannssen-Cilag, Eli-Lilly, Novartis, Sandoz and Celgene. KP has received honoraria from Abbvie, BMS, MSD, Pfizer, Roche and UCB. AR has received honoraria or research grants from Abbvie, BMS, Centocor, Eli-Lilly, Novartis, Pfizer, Roche and Wyeth. BR has received research grants as well as honoraria from Centocor, Abbott, Amgen, Aesca, UCB, Roche, MSD, Celltrion, Schering-Plough, Wyeth, Pfizer, BMS, Jannssen-Cilag, Eli-Lilly and Novartis. PS-P has received research grant honoraria from Abbvie, UCB, Roche, MSD, Pfizer, BMS, and Eli-Lilly.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.